A recent study reveals that individuals who discontinue popular GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who end conventional lifestyle programs.
Research printed in a prominent medical journal points out that while overweight individuals frequently drop substantial amounts of their total mass while on the medication, the mass comes back at an estimated rate of 0.8 kg per month once they quit.
"Users buying such treatments must be informed of the potential of rapid weight regain when the medication concludes," warns researcher Dr. Susan Jebb.
This pace of regain means a reversion to starting weight within about a year and a half.
Analyzing Therapies
The research, which looked at dozens of trials involving thousands of participants, compared the effects of the injectable medications with older methods.
Researchers note that people who lose weight through lifestyle changes alone usually experience a less rapid weight regain—approximately 100 grams monthly—post-intervention.
The Reason for the Fast Regain
Experts believe the way of the jabs is key to understanding the accelerated regain.
The injections imitate a natural hormone called GLP-1, which moderates appetite.
"Sustained high doses of GLP-1 levels far above than normal might result in the system to produce less of its endogenous hormone, and may also lessen responsiveness to its effects," noted Dr. Adam Collins, a dietetics expert.
"Stopping of this hormone supplement leads to appetite is uncontrolled, making overeating much more probable."
A Lifelong Issue?
Medical guidelines advise the injections for individuals with weight-linked health risks, accompanied by recommended diet and exercise modifications.
A number of clinicians say that, considering the likelihood of weight regain, the treatment should be considered life-long.
This view is reinforced by drug manufacturers, who note that the findings "underscore the long-term character of excess weight," akin to managing diseases like diabetes.
User Testimonies
Individuals who have come off the jabs report a intense resurgence of cravings.
"It was like a switch flipping and you're instantly starving," said one woman.
This challenge is compounded if users have not developed permanent lifestyle or habit modifications during therapy.
Widespread Adoption
Survey data show that millions of adults in the UK have used weight-loss jabs in the last 12 months, with interest remaining high.
- Adoption is higher among females than men.
- The 40s and 50s demographic shows the greatest level of interest.
- Many access the drugs through private healthcare rather than public health services.
Ultimately, clinicians emphasize that while GLP-1 drugs are effective agents for shedding pounds, they are not a magic fix and lasting health benefits likely depends on integrated behavioural changes.
